Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: J Pharmacol Sci. 2013 May 22;122(2):103–108. doi: 10.1254/jphs.13045fp

Fig. 2.

Fig. 2

Plasma (A) and renal (B) ACE activities, plasma renin activity (PRA) (C), and plasma aldosterone concentration (D). A and B: Plasma ACE activity in plasma and the kidney were unchanged by Ang I infusion. Temocapril, but not olmesartan, reduced ACE activity in both plasma and kidney. C: PRA was undetectable following Ang I infusion. Temocapril and olmesartan treatment increased PRA. D: Plasma aldosterone levels were increased by Ang I infusion. Either temocapril or olmesartan treatment suppressed the increase in plasma aldosterone level. *P < 0.05 vs. vehicle-infused group, #P < 0.05 vs. Ang I + control group, n.d.: not detectable.